{"generic":"Diclofenac Sodium","drugs":["Diclofenac Sodium","Dyloject","Pennsaid","Rexaphenac","Solaraze","Voltaren","Voltaren-XR"],"mono":[{"id":"178000-s-0","title":"Generic Names","mono":"Diclofenac Sodium"},{"id":"178000-s-1","title":"Dosing and Indications","sub":[{"id":"178000-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Actinic keratosis:<\/b> Apply TOPICALLY to lesions twice daily for 60 to 90 days<\/li><li><b>Ankylosing spondylitis:<\/b> (delayed-release [enteric-coated] tablets) 25 mg ORALLY 4 times daily with an extra 25-mg dose at bedtime if necessary<\/li><li><b>Extraction of cataract - Inflammatory disorder of the eye:<\/b> instill 1 drop into affected eye 4 times daily for 14 days, beginning 24 hours after cataract surgery<\/li><li><b>Osteoarthritis:<\/b> (delayed-release [enteric-coated] tablets) 100 to 150 mg\/day ORALLY in 2 to 3 divided doses<\/li><li><b>Osteoarthritis:<\/b> (extended-release tablets) 100 mg ORALLY once daily; if inadequate response, may increase up to a MAX of 100 mg twice daily<\/li><li><b>Osteoarthritis:<\/b> (topical 1% gel) 4 g applied TOPICALLY to lower extremities 4 times daily; 2 g applied TOPICALLY to upper extremities 4 times daily; MAX 8 g\/day to any single joint of upper extremity, 16 g\/day to any single joint of lower extremity, 32 g\/day total over all affected joints<\/li><li><b>Osteoarthritis:<\/b> (topical 1.5% solution) apply 10 drops TOPICALLY and spread around front, back, and sides of each affected knee; repeat until 40 drops have been applied; apply 4 times daily<\/li><li><b>Osteoarthritis:<\/b> (topical 2% solution) apply 40 mg (2 pump actuations) TOPICALLY to affected knee 2 times a day<\/li><li><b>Pain, acute, Mild to moderate:<\/b> 37.5 mg slow IV bolus injection over 15 seconds every 6 hours as needed; MAX dose 150 mg\/24 hours<\/li><li><b>Pain, acute, Moderate to severe; with or without opioids:<\/b> 37.5 mg slow IV bolus injection over 15 seconds every 6 hours as needed; MAX dose 150 mg\/24 hours<\/li><li><b>Pain in eye - Photophobia - Refractive keratoplasty:<\/b> instill 1 to 2 drops into affected eye within the hour before surgery and 4 times a day beginning within 15 minutes after surgery and continued for up to 3 days postoperatively<\/li><li><b>Rheumatoid arthritis:<\/b> (delayed-release [enteric-coated] tablets) 150 to 200 mg\/day ORALLY in 2 to 4 divided doses<\/li><li><b>Rheumatoid arthritis:<\/b> (extended-release tablets) 100 mg ORALLY once daily; if inadequate response, may increase up to a MAX of 100 mg twice daily<\/li><\/ul>"},{"id":"178000-s-1-5","title":"Pediatric Dosing","mono":"Safety and efficacy have not been established in pediatric patients "},{"id":"178000-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>Renal impairment:<\/b> Initiate oral therapy with lowest recommended dosage; monitor patient closely<\/li><li><b>Renal impairment, moderate to severe:<\/b> IV formulation not recommended<\/li><li><b>Renal impairment, moderate to severe, and at risk for volume depletion in postoperative period:<\/b> IV formulation contraindicated<\/li><li><b>Hepatic impairment, mild:<\/b> Dosage adjustments not necessary<\/li><li><b>Moderate to severe hepatic impairment:<\/b> IV formulation not recommended<\/li><li><b>Body weight:<\/b> Dosage adjustments not recommended with IV formulation<\/li><\/ul>"},{"id":"178000-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Actinic keratosis<\/li><li>Ankylosing spondylitis<\/li><li>Extraction of cataract - Inflammatory disorder of the eye<\/li><li>Osteoarthritis<\/li><li>Pain, acute, Mild to moderate<\/li><li>Pain, acute, Moderate to severe; with or without opioids<\/li><li>Pain in eye - Photophobia - Refractive keratoplasty<\/li><li>Rheumatoid arthritis<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Biliary colic<\/li><li>Corneal abrasion<\/li><li>Extraction of cataract - Mydriasis induction<\/li><li>Fever<\/li><li>Gout<\/li><li>Laser photocoagulation to retina<\/li><li>Migraine<\/li><li>Myalgia<\/li><li>Pain<\/li><li>Photophobia<\/li><li>Post-episiotomy pain<\/li><\/ul>"}]},{"id":"178000-s-2","title":"Black Box Warning","mono":"<ul><li><b>Intravenous (Injectable)<\/b><br\/>NSAIDs may increase the risk of serious cardiovascular thrombotic events, myocardial infarction, or stroke, which may be fatal. The risks may be greater in patients with cardiovascular disease or risk factors for cardiovascular disease. Diclofenac is contraindicated for the treatment of peri-operative pain in the setting of CABG surgery. NSAIDs can also increase the risk of serious gastrointestinal adverse events, especially in the elderly, including bleeding, ulceration, or perforation of the stomach or intestines, which may be fatal.<br\/><\/li><li><b>Oral (Tablet, Delayed Release; Tablet, Enteric Coated; Tablet, Extended Release)<\/b><br\/>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may be increased in patients with cardiovascular disease or risk factors for cardiovascular disease. Diclofenac is contraindicated for the treatment of peri-operative pain in the setting of CABG surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events especially in the elderly, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.<br\/><\/li><li><b>Topical (Gel\/Jelly; Solution)<\/b><br\/>NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may be increased in patients with cardiovascular disease or risk factors for cardiovascular disease. Diclofenac is contraindicated in the peri-operative setting of CABG surgery. NSAIDs can also cause an increased risk of serious gastrointestinal adverse events especially in the elderly, including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal.<br\/><\/li><\/ul>"},{"id":"178000-s-3","title":"Contraindications\/Warnings","sub":[{"id":"178000-s-3-9","title":"Contraindications","mono":"<ul><li>asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs, history; severe and rarely fatal anaphylactic-like reactions have been reported<\/li><li>CABG surgery, treatment of perioperative pain<\/li><li>hypersensitivity to diclofenac or any component of the product<\/li><li>mild or severe renal insufficiency and at risk for volume depletion during perioperative period<\/li><\/ul>"},{"id":"178000-s-3-10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Increased risk of serious cardiovascular thrombotic events, myocardial infarction, or stroke in patients with known cardiovascular disease or with cardiovascular risk factors<\/li><li>-- Cardiovascular thrombotic events, myocardial infarction, stroke, and fatalities have been reported; risk may increase with duration of use<\/li><li>-- Gastrointestinal adverse events (bleeding, ulceration, perforation of stomach or intestines), some potentially fatal, may occur  at any time and without warning; monitoring recommended<\/li><li>-- Increased risk of gastrointestinal effects among elderly and debilitated and with concurrent use of aspirin, corticosteroids, and anticoagulants, smoking or alcohol use, poor general health status, or with prolonged use; monitoring recommended<\/li><li>Cardiovascular:<\/li><li>- New onset or worsening hypertension may occur; NSAIDs may lessen the effects of thiazides and loop diuretics; monitoring recommended<\/li><li>-- Fluid retention and edema have been reported; increased risk with heart failure or preexisting fluid retention; monitoring recommended (oral, topical)<\/li><li>Dermatologic:<\/li><li>-- Avoid application to open wounds, infections, inflammations, or exfoliative dermatitis; absorption or tolerability may be affected<\/li><li>-- Serious skin reactions including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which may be fatal, may occur; discontinuation required<\/li><li>Gastrointestinal:<\/li><li>-- Use caution in patients with past history of gastrointestinal bleeding or ulcer disease<\/li><li>Hematologic:<\/li><li>-- Anemia may occur; monitoring recommended<\/li><li>-- May prolong bleeding time, especially in patients with coagulation disorders; monitoring recommended<\/li><li>Hepatic:<\/li><li>-- Hepatic reactions, including elevated transaminases, jaundice and fatal fulminant hepatitis, liver necrosis, and hepatic failure, have been reported; monitoring recommended and discontinuation required for symptoms of or evidence of hepatic reactions<\/li><li>-- Use not recommended in patients with moderate to severe hepatic impairment<\/li><li>Immunologic:<\/li><li>-- Anaphylactic reactions have occurred<\/li><li>-- Cross sensitivity may occur with sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, or other NSAIDs<\/li><li>-- Inflammation and fever may be masked and diminish the ability to detect infectious complications<\/li><li>Ophthalmic:<\/li><li>-- Corneal adverse events, some sight threatening, may occur in conjunction with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface disease, rheumatoid arthritis, or repeat ocular surgeries<\/li><li>-- Keratitis may occur; increased risk of epithelial breakdown, corneal thinning, corneal infiltrates, corneal erosion, corneal ulceration, and corneal perforation<\/li><li>-- Bleeding of ocular tissues (ie, hyphemas) may occur in conjunction with ocular surgery<\/li><li>-- Use not recommended more than 24 hours prior to or beyond 14 days post-surgery; increased risk of corneal adverse events<\/li><li>-- Use of the same bottle in both eyes not recommended when used in association with surgery<\/li><li>-- Avoid contact with eyes and mucosa<\/li><li>Renal:<\/li><li>-- Increased risk of renal toxicity or injury; monitoring recommended<\/li><li>-- Use not recommended in moderate to severe renal insufficiency<\/li><li>-- Use not recommended in advanced renal disease<\/li><li>-- Renal papillary necrosis and other renal injury may occur; increased risk with dehydration, prolonged use, concurrent use of ACE inhibitors and diuretics, impaired renal function, heart failure, liver dysfunction, and the elderly<\/li><li>Reproductive:<\/li><li>-- Avoid use during pregnancy<\/li><li>Respiratory:<\/li><li>-- Severe bronchospasm may occur with aspirin triad use (bronchospasm in asthmatic patients with rhinitis, with or without nasal polyps following aspirin or NSAID administration); use not recommended<\/li><li>-- Risk of severe and potentially fatal bronchospasm in patient with preexisting asthma; monitoring recommended<\/li><li>Other:<\/li><li>--Monitoring recommended in elderly patients<\/li><li>-- Slowed or delayed healing may occur<\/li><li>Concomitant use:<\/li><li>-- Concomitant use of unprescribed acetaminophen not recommended<\/li><li>-- Concomitant use of aspirin  or NSAIDs are not recommended<\/li><\/ul>"},{"id":"178000-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Diclofenac: C (1st trimester), C (2nd trimester), D (3rd trimester) (FDA)<\/li><li>Diclofenac: C (AUS)<\/li><\/ul>"},{"id":"178000-s-3-12","title":"Breast Feeding","mono":"Diclofenac: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},{"id":"178000-s-4","title":"Drug Interactions","sub":[{"id":"178000-s-4-13","title":"Contraindicated","mono":"<ul>Ketorolac (theoretical)<\/ul>"},{"id":"178000-s-4-14","title":"Major","mono":"<ul><li>Abciximab (theoretical)<\/li><li>Anagrelide (theoretical)<\/li><li>Apixaban (theoretical)<\/li><li>Ardeparin (probable)<\/li><li>Argatroban (theoretical)<\/li><li>Beta Glucan (theoretical)<\/li><li>Bivalirudin (theoretical)<\/li><li>Ceritinib (theoretical)<\/li><li>Certoparin (probable)<\/li><li>Cilostazol (theoretical)<\/li><li>Citalopram (probable)<\/li><li>Clopidogrel (probable)<\/li><li>Clovoxamine (probable)<\/li><li>Cyclosporine (established)<\/li><li>Dabigatran Etexilate (theoretical)<\/li><li>Dabrafenib (theoretical)<\/li><li>Dalteparin (probable)<\/li><li>Danaparoid (probable)<\/li><li>Deferiprone (theoretical)<\/li><li>Desirudin (theoretical)<\/li><li>Dipyridamole (theoretical)<\/li><li>Duloxetine (probable)<\/li><li>Edoxaban (established)<\/li><li>Enoxaparin (probable)<\/li><li>Eptifibatide (theoretical)<\/li><li>Erlotinib (theoretical)<\/li><li>Escitalopram (probable)<\/li><li>Femoxetine (probable)<\/li><li>Feverfew (theoretical)<\/li><li>Flesinoxan (probable)<\/li><li>Fluoxetine (probable)<\/li><li>Fluvoxamine (probable)<\/li><li>Fondaparinux (theoretical)<\/li><li>Ginkgo (probable)<\/li><li>Gossypol (theoretical)<\/li><li>Heparin (theoretical)<\/li><li>Lepirudin (theoretical)<\/li><li>Levomilnacipran (theoretical)<\/li><li>Meadowsweet (theoretical)<\/li><li>Methotrexate (probable)<\/li><li>Milnacipran (probable)<\/li><li>Nadroparin (probable)<\/li><li>Nefazodone (probable)<\/li><li>Nitisinone (theoretical)<\/li><li>Parnaparin (probable)<\/li><li>Paroxetine (probable)<\/li><li>Pemetrexed (theoretical)<\/li><li>Pentosan Polysulfate Sodium (theoretical)<\/li><li>Pentoxifylline (theoretical)<\/li><li>Pralatrexate (theoretical)<\/li><li>Prasugrel (theoretical)<\/li><li>Protein C (theoretical)<\/li><li>Reviparin (probable)<\/li><li>Rivaroxaban (theoretical)<\/li><li>Sertraline (probable)<\/li><li>Sibutramine (theoretical)<\/li><li>Tacrolimus (probable)<\/li><li>Ticlopidine (theoretical)<\/li><li>Tinzaparin (probable)<\/li><li>Tirofiban (theoretical)<\/li><li>Venlafaxine (probable)<\/li><li>Vilazodone (theoretical)<\/li><li>Vortioxetine (theoretical)<\/li><li>Zimeldine (probable)<\/li><\/ul>"},{"id":"178000-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Alacepril (established)<\/li><li>Alprenolol (probable)<\/li><li>Amiloride (probable)<\/li><li>Amlodipine (probable)<\/li><li>Arotinolol (probable)<\/li><li>Atenolol (probable)<\/li><li>Azilsartan (probable)<\/li><li>Azilsartan Medoxomil (probable)<\/li><li>Azosemide (probable)<\/li><li>Befunolol (probable)<\/li><li>Bemetizide (probable)<\/li><li>Benazepril (established)<\/li><li>Bendroflumethiazide (probable)<\/li><li>Benzthiazide (probable)<\/li><li>Bepridil (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bevantolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Bopindolol (probable)<\/li><li>Bucindolol (probable)<\/li><li>Bumetanide (probable)<\/li><li>Bupranolol (probable)<\/li><li>Buthiazide (probable)<\/li><li>Candesartan Cilexetil (probable)<\/li><li>Canrenoate (probable)<\/li><li>Captopril (established)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Chlorothiazide (probable)<\/li><li>Chlorpropamide (probable)<\/li><li>Chlorthalidone (probable)<\/li><li>Cholestyramine (probable)<\/li><li>Cilazapril (established)<\/li><li>Ciprofloxacin (established)<\/li><li>Clopamide (probable)<\/li><li>Colestipol (probable)<\/li><li>Cyclopenthiazide (probable)<\/li><li>Delapril (established)<\/li><li>Desvenlafaxine (probable)<\/li><li>Dilevalol (probable)<\/li><li>Diltiazem (probable)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Eprosartan (probable)<\/li><li>Esmolol (probable)<\/li><li>Ethacrynic Acid (probable)<\/li><li>Felodipine (probable)<\/li><li>Fluconazole (probable)<\/li><li>Flunarizine (probable)<\/li><li>Fosinopril (established)<\/li><li>Furosemide (probable)<\/li><li>Gallopamil (probable)<\/li><li>Glimepiride (probable)<\/li><li>Glipizide (probable)<\/li><li>Glyburide (probable)<\/li><li>Hydrochlorothiazide (probable)<\/li><li>Hydroflumethiazide (probable)<\/li><li>Imidapril (established)<\/li><li>Indapamide (probable)<\/li><li>Irbesartan (probable)<\/li><li>Isradipine (probable)<\/li><li>Labetalol (probable)<\/li><li>Lacidipine (probable)<\/li><li>Landiolol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Lidoflazine (probable)<\/li><li>Lisinopril (established)<\/li><li>Lithium (probable)<\/li><li>Losartan (probable)<\/li><li>Manidipine (probable)<\/li><li>Mepindolol (probable)<\/li><li>Methyclothiazide (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metolazone (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moexipril (established)<\/li><li>Nadolol (probable)<\/li><li>Nateglinide (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nicardipine (probable)<\/li><li>Nifedipine (probable)<\/li><li>Nilvadipine (probable)<\/li><li>Nimodipine (probable)<\/li><li>Nipradilol (probable)<\/li><li>Nisoldipine (probable)<\/li><li>Nitrendipine (probable)<\/li><li>Olmesartan Medoxomil (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Pentopril (established)<\/li><li>Perindopril (established)<\/li><li>Pindolol (probable)<\/li><li>Piretanide (probable)<\/li><li>Polythiazide (probable)<\/li><li>Pranidipine (probable)<\/li><li>Propranolol (probable)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Repaglinide (probable)<\/li><li>Sotalol (probable)<\/li><li>Spirapril (established)<\/li><li>Spironolactone (probable)<\/li><li>Talinolol (probable)<\/li><li>Tasosartan (probable)<\/li><li>Telmisartan (probable)<\/li><li>Temocapril (established)<\/li><li>Tertatolol (probable)<\/li><li>Timolol (probable)<\/li><li>Tolazamide (probable)<\/li><li>Tolbutamide (probable)<\/li><li>Torsemide (probable)<\/li><li>Trandolapril (established)<\/li><li>Triamterene (probable)<\/li><li>Trichlormethiazide (probable)<\/li><li>Valsartan (probable)<\/li><li>Verapamil (probable)<\/li><li>Xipamide (probable)<\/li><li>Zofenopril (established)<\/li><\/ul>"}]},{"id":"178000-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Dermatologic:<\/b>Application site reaction (Topical, up to 84%)<\/li><li><b>Hematologic:<\/b>Blood coagulation disorder<\/li><li><b>Ophthalmic:<\/b>Burning sensation in eye (Ophthalmic, 15%), Keratitis (Ophthalmic, up to 28%), Lacrimation and lacrimal drainage - finding (Ophthalmic or topical, up to 30%), Raised intraocular pressure (Ophthalmic, up to 15%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Congestive heart failure, Hypertension (Topical, Up to 2%), Myocardial infarction, Thrombotic tendency observations<\/li><li><b>Dermatologic:<\/b>Erythema multiforme, Generalized exfoliative dermatitis, Stevens-Johnson syndrome, Toxic epidermal necrolysis<\/li><li><b>Gastrointestinal:<\/b>Gastrointestinal perforation, Or hemorrhage, Gastrointestinal ulcer (1% to 10%), Inflammatory disorder of digestive tract, Melena, Pancreatitis<\/li><li><b>Hematologic:<\/b>Agranulocytosis, Aplastic anemia, Hemolytic anemia<\/li><li><b>Hepatic:<\/b>Fulminant hepatitis, Hepatic necrosis, Jaundice, Liver failure<\/li><li><b>Immunologic:<\/b>Anaphylactoid reaction, Sepsis<\/li><li><b>Neurologic:<\/b>Cerebrovascular accident, Seizure<\/li><li><b>Renal:<\/b>Acute renal failure, Papillary necrosis<\/li><li><b>Other:<\/b>Angioedema<\/li><\/ul>"},{"id":"178000-s-6","title":"Drug Name Info","sub":{"0":{"id":"178000-s-6-17","title":"US Trade Names","mono":"<ul><li>Solaraze<\/li><li>Voltaren<\/li><li>Voltaren-XR<\/li><li>Pennsaid<\/li><li>Rexaphenac<\/li><li>Dyloject<\/li><\/ul>"},"2":{"id":"178000-s-6-19","title":"Class","mono":"<ul><li>Acetic Acid (class)<\/li><li>Analgesic<\/li><li>Anti-Inflammatory<\/li><li>NSAID<\/li><li>Ophthalmologic Agent<\/li><\/ul>"},"3":{"id":"178000-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"178000-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},{"id":"178000-s-7","title":"Mechanism Of Action","mono":"Diclofenac sodium, a phenylacetic acid, is an NSAID that demonstrates analgesic, antipyretic and antiinflammatory activity. The precise mechanism of action is still unknown, but is thought to be related to prostaglandin synthetase inhibition. The mechanism of action of diclofenac sodium in the treatment of actinic keratosis is unknown.<br\/>"},{"id":"178000-s-8","title":"Pharmacokinetics","sub":[{"id":"178000-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, IV: 5 minutes<\/li><li>Tmax, Oral: 2.3 to 6.5 hours<\/li><li>Tmax, Topical 1% gel: 10 to 14 hours<\/li><li>Tmax, Topical 3% gel: 4.5 hours<\/li><li>Tmax, Topical 1.5% solution: 4 hours<\/li><li>Bioavailability, Oral: approximately 50%<\/li><li>Bioavailability, Ophthalmic: limited<\/li><li>Bioavailability, Topical 1% gel: 6% of systemic exposure associated with oral dosing<\/li><li>Bioavailability, Topical 3% gel: 10%<\/li><li>Bioavailability, Topical 1.5% solution: 33% of systemic exposure associated with topical gel<\/li><li>Effect of food, oral, immediate-release tablet: delays absorption by 1 to 4.5 hours and reduces Cmax by less than 20%<\/li><li>Effect of food, oral, extended-release tablet: delays Tmax by 1 to 2 hours and 2-fold increase in Cmax<\/li><\/ul>"},{"id":"178000-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: greater than 99%<\/li><li>Vd, IV: 40.1 to 83.4 L<\/li><li>Vd, Oral: 1.4 L\/kg<\/li><\/ul>"},{"id":"178000-s-8-25","title":"Metabolism","mono":"<ul><li>Liver: Extensive<\/li><li>4'-hydroxy-diclofenac: Weakly active<\/li><li>Substrate of CYP2C9, CYP3A4, and possibly CYP2C8<\/li><\/ul>"},{"id":"178000-s-8-26","title":"Excretion","mono":"<ul><li>Biliary: 35% as unchanged conjugates and metabolites<\/li><li>Renal: 65%; little unchanged drug<\/li><li>Total body clearance, IV: 387 mL\/min<\/li><li>Total body clearance, Oral: 82 to 895 mL\/min<\/li><li>Total body clearance, Topical 1.5% solution: 244.7 L\/hr<\/li><\/ul>"},{"id":"178000-s-8-27","title":"Elimination Half Life","mono":"<ul><li>IV: 2.29 hours<\/li><li>Oral: approximately 2 hours<\/li><li>Topical 1.5% solution: 79 hours<\/li><li>Metabolites: 1 to 3 hours<\/li><\/ul>"}]},{"id":"178000-s-9","title":"Administration","mono":"<ul><li><b>Intravenous<\/b><br\/><ul><li>For IV use only<\/li><li>Hydrate patient prior to drug administration<\/li><li>Do not use parenteral solution if particulate matter, discoloration, or foreign particulates are present<\/li><\/ul><\/li><li><b>Ophthalmic<\/b><br\/>Do not use with soft contact lenses; may use with bandage hydrogel soft contact lenses<br\/><\/li><li><b>Topical<\/b><br\/><ul><li>Prime pump before first use; fully depress pump mechanism (actuation) 4 times while holding bottle upright; discard any portion dispensed (2% solution).<\/li><li>Avoid exposure of application site to sunlight (1% gel, 1.5% solution, 2% solution).<\/li><li>Do not apply external heat or occlusive dressings to application site (1% gel, 1.5% solution, 2% solution).<\/li><li>Avoid concomitant use of sunscreens, cosmetics, lotions, moisturizers, insect repellants, or other topical medications (1% gel, 1.5% solution, 2% solution).<\/li><li>Avoid skin-to-skin contact with others until skin is dry (1.5% solution, 2% solution).<\/li><li>Measure the proper amount of gel using the supplied dosing cards (1% topical gel).<\/li><li>Apply the gel within the oblong area of the dosing card up to either the 2 g or 4 g line (1% topical gel).<\/li><li>Use the card to apply the gel and then gently rub gel into the skin (1% topical gel).<\/li><li>After using, hold dosing card with fingertips, rinse and dry (1% topical gel)<\/li><\/ul><\/li><\/ul>"},{"id":"178000-s-10","title":"Monitoring","mono":"<ul><li>osteoarthritis\/rheumatoid arthritis: decreased painful\/swollen joints, improved range of motion, and reduced early morning stiffness are indicative of efficacy<\/li><li>ophthalmic analgesic: relief of postoperative ophthalmic inflammation and temporary relief of pain and photophobia during surgery are indicative of efficacy<\/li><li>(oral, topical) renal function; in patients with advanced renal disease<\/li><li>(IV, oral, topical) transaminase levels; within 4 to 8 weeks after diclofenac initiation and periodically thereafter in patients receiving long-term diclofenac therapy<\/li><li>(IV, oral, topical) CBC; periodically in patients receiving long-term diclofenac therapy, including platelet function in patients with coagulation disorders or those receiving anticoagulants concomitantly<\/li><li>(IV) chemistry profile; periodically in patients on long-term therapy<\/li><li>(IV, oral, topical) blood pressure; at baseline and throughout the course of diclofenac therapy<\/li><li>(IV, oral, topical) signs and symptoms of gastrointestinal ulceration and bleeding<\/li><li>(topical) fluid status and cardiac function; in patients with fluid retention or heart failure<\/li><li>(topical) worsening asthma symptoms; in patients with preexisting asthma<\/li><li>(IV) signs and symptoms of serious cardiovascular events<\/li><li>(ophthalmic) refractory stability; in patients receiving diclofenac during corneal refractive procedures; for 1 year after treatment<\/li><\/ul>"},{"id":"178000-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/><ul><li>Ophthalmic Solution: 0.1 %<\/li><li>Oral Tablet, Enteric Coated: 25 MG, 50 MG, 75 MG<\/li><li>Oral Tablet, Extended Release: 100 MG<\/li><li>Topical Gel\/Jelly: 3 %<\/li><li>Topical Solution: 1.5 %<\/li><\/ul><\/li><li><b>Pennsaid<\/b><br\/>Topical Solution: 1.5 %, 2 %<br\/><\/li><li><b>Rexaphenac<\/b><br\/>Topical Cream: 1 %<br\/><\/li><li><b>Solaraze<\/b><br\/>Topical Gel\/Jelly: 3 %<br\/><\/li><li><b>Voltaren Gel<\/b><br\/>Topical Gel\/Jelly: 1 %<br\/><\/li><li><b>Voltaren<\/b><br\/><ul><li>Ophthalmic Solution: 0.1 %<\/li><li>Oral Tablet, Enteric Coated: 25 MG, 50 MG, 75 MG<\/li><\/ul><\/li><\/ul>"},{"id":"178000-s-12","title":"Toxicology","sub":[{"id":"178000-s-12-31","title":"Clinical Effects","mono":"<b>NONSTEROIDAL ANTIINFLAMMATORY DRUGS<\/b><br\/>USES: Nonsteroidal antiinflammatory drugs (NSAIDs) are used acutely for fever and pain control and for the treatment of several rheumatologic conditions. NOTE: Salicylates, ibuprofen, naproxen, indomethacin, phenylbutazone, mefenamic acid, ketoprofen, and the COX-2 inhibitors (celecoxib, meloxicam, rofecoxib, valdecoxib) are covered under separate managements. PHARMACOLOGY: NSAIDs include at least 20 drugs that share the cyclooxygenase enzyme inhibition leading to decreased prostaglandin production and decreased pain and inflammation. TOXICOLOGY: NSAIDs cause gastrointestinal (GI) irritation directly, and by inhibiting cyclooxygenase 1 (COX-1), which is necessary for the formation of the prostaglandins PG12 and PGE2; decrease in these prostaglandins results in decreased tissue mucus and bicarbonate secretion, increased hydrochloride secretion, and decreased gastric blood flow. The acidosis associated with severe NSAID overdose appears to result from the formation acidic metabolites, and mild hypotension. Prostaglandin inhibition by NSAIDs also causes renal arteriolar constriction, reduced renal blood flow and subsequent renal insufficiency in patients with conditions characterized by high angiotensin and low intravascular volume (eg, congestive heart failure, cirrhosis, hypovolemia). COX-1 inhibition also decreases the formation of thromboxane A2 which is necessary for platelet aggregation, predisposing patients to bleeding. EPIDEMIOLOGY: NSAID overdose is common, but severe toxicity and deaths are very rare. MILD TO MODERATE TOXICITY: Most patients with an NSAID overdose are asymptomatic or have mild GI upset (ie, nausea, vomiting, abdominal pain), and sometimes hematemesis. SEVERE TOXICITY: Massive overdose can cause seizures, delirium, coma, hypotension, renal failure, hepatic dysfunction, hypoprothrombinemia, gastrointestinal bleeding, hyperkalemia and metabolic acidosis. ADVERSE EFFECTS: Dyspepsia, ulceration perforation, GI hemorrhage, acute renal failure, fluid retention, interstitial nephritis, nephrotic syndrome, asthma exacerbation, headache and aseptic meningitis may develop. Agranulocytosis, aplastic anemia, and thrombocytopenia have developed, but appear to be idiosyncratic reactions. VETERINARY\/FLURBIPROFEN: Pets exposed to topical pain medications containing flurbiprofen may be at risk of developing significant illness and death. The FDA has received reports of severe illness in several households where pet owners applied the topical medication to themselves (ie, neck and feet). In these cases, it was unclear how the cats became exposed. However, 2 cats in one household developed renal failure and recovered with supportive care and 2 cats in another household developed lethargy, vomiting, melena, and anemia and died despite care. <br\/>"},{"id":"178000-s-12-32","title":"Treatment","mono":"<b>NONSTEROIDAL ANTIINFLAMMATORY DRUGS <\/b><br\/><ul><li>Support: MANAGEMENT OF MILD TO MODERATE TOXICITY: Most toxicity related to NSAID exposure resolves with supportive care; otherwise, healthy patients with a history of NSAID poisoning generally require only gastrointestinal decontamination with activated charcoal, and fluid and electrolyte replacement. SEVERE TOXICITY: Endotracheal intubation and mechanical ventilation may be necessary in patients with CNS depression or recurrent seizures. Treat seizures with benzodiazepines, and hypotension with fluids, adding adrenergic vasopressors, if necessary.<\/li><li>Decontamination: PREHOSPITAL: Activated charcoal can be given after a large overdose. HOSPITAL: Activated charcoal binds NSAIDs, but is usually not required as severe toxicity is rare. Charcoal should be administered after a large, recent overdose. Gastric lavage is generally not indicated as life threatening toxicity is very rare.<\/li><li>Airway management: Intubation and mechanical ventilation should be considered for patients who present with CNS depression.<\/li><li>Antidote: None.<\/li><li>Monitoring of patient: Measurement of serum concentrations of NSAIDs are widely available, but are not useful in guiding clinical management. Serum electrolytes, creatinine and BUN concentrations should be measured in patients with an intentional overdose. If significant CNS or respiratory toxicity is present, acid-base status should be assessed. Obtain a serum acetaminophen and salicylate concentration. Monitor vital signs.<\/li><li>Enhanced elimination procedure: NSAIDs are highly protein bound and extensively metabolized; therefore, hemodialysis is unlikely to be effective.<\/li><li>Patient disposition: HOME CRITERIA: Inadvertent exploratory ingestions in asymptomatic children can generally be managed with dilution and observation at home. OBSERVATION CRITERIA: Patients with a large or deliberate ingestion should be observed for 4 to 6 hours. If they remain asymptomatic with normal laboratory evaluation, they may be discharged after appropriate psychiatric evaluation. ADMISSION CRITERIA: Patients who may have ingested a large dose of NSAIDs and who present with CNS or cardiovascular toxicity or metabolic acidosis, or who have a known risk factor for organ system toxicity associated with NSAIDs should be considered at higher risk of complications and warrant admission.<\/li><\/ul>"},{"id":"178000-s-12-33","title":"Range of Toxicity","mono":"<b>NONSTEROIDAL ANTIINFLAMMATORY DRUGS<\/b><br\/>TOXICITY: The toxic dose varies with each NSAID, but significant symptoms can occur after ingestion of 5 to 10 times the therapeutic dose. THERAPEUTIC DOSE: Varies by agent. <br\/>"}]},{"id":"178000-s-13","title":"Clinical Teaching","mono":"<ul><li>Warn female patients to avoid use during pregnancy after 30 weeks gestation.<\/li><li>The topical formulation of this drug can cause sun-sensitivity. Advise patient to avoid exposure to sunlight and tanning beds.<\/li><li>Side effects may include edema, abdominal pain, diarrhea, dyspepsia, flatulence, dizziness, headache, bronchospasm, or tinnitus. Ophthalmic side effects may also include a burning sensation, conjunctivitis, corneal deposit\/opacity\/edema, or discharge from eye. Topical side effects may also include application site skin reactions (eg, dry skin, contact dermatitis).<\/li><li>Injectable side effects may include nausea, constipation, infusion site pain, infusion site extravasation, fever, or insomnia.<\/li><li>Advise patient to report and to seek medical help for symptoms of serious cardiovascular events, such as myocardial infarction or stroke (chest pain, shortness of breath, weakness, slurring of speech).<\/li><li>Instruct patient to report symptoms of serious gastrointestinal adverse events, such as bleeding, ulceration, and perforation of stomach or intestines (epigastric pain, dyspepsia, melena, hematemesis).<\/li><li>Instruct patient to report symptoms of hepatotoxicity (nausea, fatigue, lethargy, pruritus, jaundice, right upper quadrant tenderness, and flu-like symptoms).<\/li><li>Patient should promptly report symptoms of serious skin adverse events, including exfoliative dermatitis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, and anaphylactoid reactions (skin rash, blistering, fever, itching, difficulty breathing, swelling of the face or throat, or other hypersensitivity symptoms).<\/li><li>Advise patient to promptly report unexplained weight gain or edema.<\/li><li>Patient should take tablet with a full glass of water, food, or milk to minimize gastric irritation.<\/li><li>Instruct patient on proper instillation technique of ophthalmic formulation.<\/li><li>Tell patient using ophthalmic form to avoid wearing soft contact lenses during drug therapy.<\/li><li>Instruct patient using topical form to avoid applying this drug to open wounds, infections, inflamed areas, or exfoliative dermatitis, and to avoid contact of this drug with eyes and mucous membranes<\/li><li>Patient should avoid showering, bathing or washing any area where drug is applied, including treated hands, for at least 30 minutes to 1 hour after topical application of this drug.<\/li><li>Patient should wait until the area treated with the topical form is completely dry before applying sunscreen, insect repellant, lotion, moisturizer, cosmetics, or other topical medications.<\/li><li>Advise patient to avoid skin-to-skin contact with other people until the area treated with the topical form is completely dry<\/li><li>Patient should not use occlusive dressing or external heat over areas treated with the topical formulation.<\/li><li>Aspirin should be avoided while taking drug.<\/li><li>Patient should not drink alcohol while taking oral form of this drug.<\/li><li>Tell patient to avoid use of additional NSAIDs during therapy, unless approved by healthcare professional.<\/li><li>Patient using ophthalmic form should not use other ophthalmic medications, unless approved by healthcare professional.<\/li><\/ul>"}]}